vs

Side-by-side financial comparison of Dexcom (DXCM) and Synopsys (SNPS). Click either name above to swap in a different company.

Synopsys is the larger business by last-quarter revenue ($2.3B vs $1.3B, roughly 1.8× Dexcom). Dexcom runs the higher net margin — 21.2% vs 19.9%, a 1.3% gap on every dollar of revenue. On growth, Synopsys posted the faster year-over-year revenue change (50.6% vs 21.6%). Over the past eight quarters, Synopsys's revenue compounded faster (16.9% CAGR vs 12.0%).

Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.

Synopsys, Inc. is an American multinational electronic design automation (EDA) company headquartered in Sunnyvale, California, that focuses on design and verification of silicon chips, electronic system-level design and verification, and reusable components. Synopsys supplies tools and services to the semiconductor design and manufacturing industry.

DXCM vs SNPS — Head-to-Head

Bigger by revenue
SNPS
SNPS
1.8× larger
SNPS
$2.3B
$1.3B
DXCM
Growing faster (revenue YoY)
SNPS
SNPS
+29.0% gap
SNPS
50.6%
21.6%
DXCM
Higher net margin
DXCM
DXCM
1.3% more per $
DXCM
21.2%
19.9%
SNPS
Faster 2-yr revenue CAGR
SNPS
SNPS
Annualised
SNPS
16.9%
12.0%
DXCM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DXCM
DXCM
SNPS
SNPS
Revenue
$1.3B
$2.3B
Net Profit
$267.3M
$448.7M
Gross Margin
62.9%
71.0%
Operating Margin
25.6%
5.4%
Net Margin
21.2%
19.9%
Revenue YoY
21.6%
50.6%
Net Profit YoY
153.6%
-59.7%
EPS (diluted)
$0.67
$2.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DXCM
DXCM
SNPS
SNPS
Q1 26
$1.3B
Q4 25
$1.3B
$2.3B
Q3 25
$1.2B
$1.7B
Q2 25
$1.2B
$1.6B
Q1 25
$1.0B
$1.5B
Q4 24
$1.1B
$1.5B
Q3 24
$994.2M
$1.5B
Q2 24
$1.0B
$1.5B
Net Profit
DXCM
DXCM
SNPS
SNPS
Q1 26
$267.3M
Q4 25
$267.3M
$448.7M
Q3 25
$283.8M
$242.5M
Q2 25
$179.8M
$345.3M
Q1 25
$105.4M
$295.7M
Q4 24
$151.7M
$1.1B
Q3 24
$134.6M
$408.1M
Q2 24
$143.5M
$292.1M
Gross Margin
DXCM
DXCM
SNPS
SNPS
Q1 26
62.9%
Q4 25
62.9%
71.0%
Q3 25
60.5%
78.1%
Q2 25
59.5%
80.2%
Q1 25
56.9%
81.4%
Q4 24
58.9%
78.3%
Q3 24
59.7%
80.9%
Q2 24
62.4%
79.4%
Operating Margin
DXCM
DXCM
SNPS
SNPS
Q1 26
25.6%
Q4 25
25.6%
5.4%
Q3 25
20.1%
9.5%
Q2 25
18.4%
23.5%
Q1 25
12.9%
17.3%
Q4 24
17.0%
20.3%
Q3 24
15.3%
23.6%
Q2 24
15.7%
22.8%
Net Margin
DXCM
DXCM
SNPS
SNPS
Q1 26
21.2%
Q4 25
21.2%
19.9%
Q3 25
23.5%
13.9%
Q2 25
15.5%
21.5%
Q1 25
10.2%
20.3%
Q4 24
13.6%
74.4%
Q3 24
13.5%
26.7%
Q2 24
14.3%
20.1%
EPS (diluted)
DXCM
DXCM
SNPS
SNPS
Q1 26
$0.67
Q4 25
$0.67
$2.44
Q3 25
$0.70
$1.50
Q2 25
$0.45
$2.21
Q1 25
$0.27
$1.89
Q4 24
$0.37
$7.13
Q3 24
$0.34
$2.61
Q2 24
$0.35
$1.88

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DXCM
DXCM
SNPS
SNPS
Cash + ST InvestmentsLiquidity on hand
$917.7M
$3.0B
Total DebtLower is stronger
$13.5B
Stockholders' EquityBook value
$2.7B
$28.3B
Total Assets
$6.3B
$48.2B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DXCM
DXCM
SNPS
SNPS
Q1 26
$917.7M
Q4 25
$917.7M
$3.0B
Q3 25
$1.8B
$2.6B
Q2 25
$1.2B
$14.3B
Q1 25
$904.9M
$3.8B
Q4 24
$606.1M
$4.1B
Q3 24
$621.2M
$2.0B
Q2 24
$939.2M
$1.7B
Total Debt
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
$13.5B
Q3 25
$14.3B
Q2 25
$10.1B
Q1 25
Q4 24
Q3 24
Q2 24
Stockholders' Equity
DXCM
DXCM
SNPS
SNPS
Q1 26
$2.7B
Q4 25
$2.7B
$28.3B
Q3 25
$2.7B
$27.6B
Q2 25
$2.6B
$9.9B
Q1 25
$2.3B
$9.3B
Q4 24
$2.1B
$9.0B
Q3 24
$2.0B
$7.7B
Q2 24
$2.4B
$7.2B
Total Assets
DXCM
DXCM
SNPS
SNPS
Q1 26
$6.3B
Q4 25
$6.3B
$48.2B
Q3 25
$7.5B
$48.2B
Q2 25
$7.3B
$23.8B
Q1 25
$6.8B
$13.0B
Q4 24
$6.5B
$13.1B
Q3 24
$6.4B
$11.6B
Q2 24
$6.8B
$11.0B
Debt / Equity
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
0.48×
Q3 25
0.52×
Q2 25
1.01×
Q1 25
Q4 24
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DXCM
DXCM
SNPS
SNPS
Operating Cash FlowLast quarter
$639.7M
Free Cash FlowOCF − Capex
$605.2M
FCF MarginFCF / Revenue
26.8%
Capex IntensityCapex / Revenue
1.5%
Cash ConversionOCF / Net Profit
1.43×
TTM Free Cash FlowTrailing 4 quarters
$1.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
$294.0M
$639.7M
Q3 25
$659.9M
$671.0M
Q2 25
$303.0M
$275.4M
Q1 25
$183.8M
$-67.5M
Q4 24
$301.4M
$562.8M
Q3 24
$199.5M
$455.4M
Q2 24
$279.4M
$476.6M
Free Cash Flow
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
$192.1M
$605.2M
Q3 25
$579.4M
$632.4M
Q2 25
$208.9M
$219.8M
Q1 25
$96.8M
$-108.2M
Q4 24
$176.8M
$558.4M
Q3 24
$88.3M
$415.4M
Q2 24
$213.3M
$438.2M
FCF Margin
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
15.3%
26.8%
Q3 25
47.9%
36.3%
Q2 25
18.1%
13.7%
Q1 25
9.3%
-7.4%
Q4 24
15.9%
37.3%
Q3 24
8.9%
27.2%
Q2 24
21.2%
30.1%
Capex Intensity
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
8.1%
1.5%
Q3 25
6.7%
2.2%
Q2 25
8.1%
3.5%
Q1 25
8.4%
2.8%
Q4 24
11.2%
0.3%
Q3 24
11.2%
2.6%
Q2 24
6.6%
2.6%
Cash Conversion
DXCM
DXCM
SNPS
SNPS
Q1 26
Q4 25
1.10×
1.43×
Q3 25
2.33×
2.77×
Q2 25
1.69×
0.80×
Q1 25
1.74×
-0.23×
Q4 24
1.99×
0.51×
Q3 24
1.48×
1.12×
Q2 24
1.95×
1.63×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DXCM
DXCM

Segment breakdown not available.

SNPS
SNPS

License And Maintenance$940.7M42%
Other$640.0M28%
Design IP Segment$407.1M18%
KR$236.9M11%
Sales Based Royalties$30.1M1%

Related Comparisons